The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
OncoDNA has launched two new precision cancer medicine projects, the budgets for which total €16 million and are being supported in part by the Belgian Walloon Region.
The study also found that esophageal squamous cell carcinomas resemble head and neck cancer, while esophageal adenocarcinomas are similar to gastric cancers.
Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.
Genome sequencing on more than 100 esophageal adenocarcinoma tumors led to structural rearrangements and three esophageal adenocarcinoma mutational subtypes.
Researchers uncovered ties between a germline VSIG10L mutation, inherited forms of Barrett esophagus, and related esophageal cancer cases.
The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.
Researchers will develop PCR and next-generation sequencing assays for aberrantly methylated vimentin, with the goal of commercializing a screening test.
Foundation's NGS test also found clinically actionable genomic alterations in more than 90 percent of patient samples.
In PNAS this week: role for metabolomics in personalized medicine, vaginal microbiome shift linked to preterm birth, and more.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.